Araceli Elizalde, MD
Allergy & Immunology · San Antonio, TXNPI 1811174873
Payments from drug & device makers
Across 410 payments — averaging $124.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$20K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- Sanofi US Services Inc.$10K
- ADMA Biomanufacturing LLC$2K
- Pharming Healthcare, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $6K from 27 others
What the payments were for
- Consulting fees$10,96221%
- Speaking & faculty fees$29,28957%
- Travel & lodging$2,1764%
- Food & beverage$8,58517%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 37 | $19,708 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $10,698 |
| Sanofi US Services Inc. | 5 | $9,571 |
| ADMA Biomanufacturing LLC | 11 | $2,236 |
| Pharming Healthcare, Inc. | 7 | $1,722 |
| Regeneron Healthcare Solutions, Inc. | 50 | $1,216 |
| CSL Behring | 28 | $619 |
| GSK | 32 | $607 |
| Sanofi-aventis U.S. LLC | 29 | $605 |
| Sanofi | 15 | $501 |
| Genentech USA, Inc. | 17 | $436 |
| Grifols USA, LLC | 23 | $396 |
| AstraZeneca | 20 | $382 |
| Tersera Therapeutics LLC | 1 | $370 |
| Amgen(2 entities) | 20 | $367 |
| Pfizer | 10 | $340 |
| Octapharma USA, Inc. | 16 | $315 |
| Kaleo, Inc. | 8 | $183 |
| Alk-abello, Inc | 9 | $164 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $140 |
| Novartis | 3 | $82 |
| Greer Laboratories, Inc. | 3 | $70 |
| Optinose US, Inc. | 3 | $64 |
| GC Biopharma USA, Inc. | 2 | $52 |
| Hikma Pharmaceuticals USA | 3 | $47 |
| Organon | 3 | $40 |
| Galderma Laboratories, L.p. | 2 | $37 |
| LEO Pharma Inc. | 1 | $28 |
| Bio Products Laboratory USA, Inc. | 1 | $28 |
| Shire North American Group Inc | 1 | $26 |
| Incyte Corporation | 1 | $18 |
| Itamar Medical Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,098 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 23 | $197 |
| Esomeprazole Magnesium | 11 | $189 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in San Antonio
- Erika GonzalezSan Antonio$2.2M
- Joseph DiazSan Antonio$1.8M
- Robert JacobsSan Antonio$757K
- Robert RamirezSan Antonio$562K
- Lukena KarkhanisSan Antonio$377K
- John DiceSan Antonio$188K
- Mark StahlSan Antonio$51K
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.